Qube Research & Technologies (QRT)
KRYS icon

Qube Research & Technologies (QRT)’s Krystal Biotech KRYS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,523
Closed -$805K – 4326
2024
Q1 		$805K Sell
4,523
-431
-9% -$59.9K ﹤0.01% 2270
2023
Q4 		$615K Sell
4,954
-8,156
-62% -$904K ﹤0.01% 2178
2023
Q3 		$1.52M Buy
13,110
+3,305
+34% +$403K ﹤0.01% 1531
2023
Q2 		$1.15M Buy
+9,805
New +$1M ﹤0.01% 1246
2023
Q1 		– Sell
-19,224
Closed -$1.52M – 2810
2022
Q4 		$1.52M Buy
+19,224
New +$1.43M 0.01% 1046
2021
Q4 		– Sell
-7,292
Closed -$381K – 2761
2021
Q3 		$381K Buy
7,292
+1,307
+22% +$77.4K ﹤0.01% 1368
2021
Q2 		$407K Buy
+5,985
New +$418K ﹤0.01% 1392
2020
Q3 		– Sell
-4,964
Closed -$206K – 1919
2020
Q2 		$206K Buy
+4,964
New +$239K ﹤0.01% 1424
2020
Q1 		– Sell
-8,962
Closed -$496K – 1420
2019
Q4 		$496K Buy
+8,962
New +$440K 0.02% 957

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Qube Research & Technologies (QRT)'s KRYS Position: Q2 2024 in Review

Qube Research & Technologies (QRT) sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 4,523 shares — an estimated $805K sold.

Qube Research & Technologies (QRT) first reported a position in KRYS in Q4 2019 and held it in 9 quarters. The position peaked at $1.52M in Q4 2022. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

  • Qube Research & Technologies (QRT) reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 4,523 Krystal Biotech shares in Q2 2024, an estimated $805K.
  • Qube Research & Technologies (QRT) first reported a position in Krystal Biotech in Q4 2019 and held it in 9 quarters.
  • Qube Research & Technologies (QRT)'s Krystal Biotech position peaked at $1.52M in Q4 2022.
  • 245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2024, filed 14 Aug 2024.